Emerging topical treatments for psoriasis

Expert Opinion on Emerging Drugs

Volumn 18, Issue 4, 2013, Pages 523-532

  Kivelevitch, Dario N ^a   Hebeler, Katherine R ^a   Patel, Mahir ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Psoriasis; Therapeutics; Topical administration

Indexed keywords

AN 2728; ANTIPSORIASIS AGENT; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; BIMOSIAMOSE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CORTICOSTEROID; CT 327; E 6201; LAS 41004; LEO 90100; M 518101; OCHROMYCINONE; PH 10; PLACEBO; RETINOID; RUXOLITINIB; STA 21; TACROLIMUS; TAR; TOFACITINIB; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; WBI 1001;

ABNORMAL LABORATORY RESULT; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE BURNING; APPLICATION SITE DRYNESS; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ATOPIC DERMATITIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL DIVISION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHILDHOOD DISEASE; CROHN DISEASE; CYTOKINE PRODUCTION; DERMATITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ELECTROCARDIOGRAM; FOLLICULITIS; GRAFT REJECTION; HUMAN; HYPERCALCEMIA; HYPERPIGMENTATION; HYPOPIGMENTATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LYMPHOCYTIC INFILTRATION; PAIN; PAPULE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN ATROPHY; SKIN EXFOLIATION; SKIN IRRITATION; SKIN PRURITUS; TACHYPHYLAXIS; TOPICAL TREATMENT; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DERMATOLOGIC AGENTS; DRUG DISCOVERY; HUMANS; JANUS KINASES; PSORIASIS; STAT TRANSCRIPTION FACTORS; TREATMENT OUTCOME; VITAMIN D;

EID: 84888866317     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.861418     Document Type: Review

References (60)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
3. Becher B, Pantelyushin S. Hiding under the skin: interleukin-17-producing gammadelta T cells go under the skin? Nat Med 2012;18:1748-50
4. Krueger JG. Hiding under the skin: a welcome surprise in psoriasis. Nat Med 2012;18:1750-1
5. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
6. Zhu B, Edson-Heredia E, Cameron G, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase 2 study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2013; [Epub ahead of print]
7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59
8. Mason AR, Mason JM, Cork MJ, et al. Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. Br J Dermatol 2013;169:519-27
9. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15; quiz 6-8
10. Dovonex prescribing information. LEO Pharma, Inc.1 Sylvan Way Parsippany NJ 07054 USA. 2013. Available from: http://www.leopharma. us/Files/Billeder/LEO- local-images/LEO-Pharma.US/PI% 20-%20Dovonex%20Cream.pdf [Last accessed 23 October 2013]
11. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29:3-9
12. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009;29:247-56
13. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007;178:2623-9
14. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007;8:364-72
15. Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008;50:1-14
16. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007;6:17-26
17. Song H, Wang R, Wang S, Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102:4700-5
18. Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol 2011;131:108-17
19. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169:137-45
20. Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012;67:658-64
21. Patel M, Day A, Warren RB, Menter A. Emerging therapies for the treatment of psoriasis. Dermatol Ther 2012;2:16
22. CT327: Late-stage topical TrkA kinase inhibitor. Creabilis SA. 2013. Available from: http://www. creabilis-sa.com/ct-327/[Last accessed 3 September 2013]
23. Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris. Creabilis SA. 2011. Available from: http://www. creabilis-sa.com/news/24/75/Creabilis-Announces-Positive-Phase-IIa-Results-for- TrkA-Kinase-Inhibitor-CT327-in-Psoriasis-Vulgaris.html [Last accessed 03 September 2013]
24. Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327. Creabilis SA. 2013. Available from: http://www. creabilis-sa.com/news/11/75/Creabilis-Announces-Headline-Results-of-its-Phase- 2b-Trial-of-Topical-TrkA-Kinase-Inhibitor-CT327.html [Last accessed 03 September 2013]
25. Goto M, Chow J, Muramoto K, et al. E6201 [(3S,4R,5Z,8S,9S,11E)-14- (ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2- benzoxacyclotetradecine-1,7 (8H)-dione], a novel kinase inhibitor of mitogenactivated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. J Pharmacol Exp Ther 2009;331:485-95
26. Muramoto K, Goto M, Inoue Y, et al. E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther 2010;335:23-31
27. A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris. Eisai, Inc. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT01268527? term=E6201&rank=1 [Last accessed 04 September 2013]
28. Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis. Eisai, Inc. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT00539929? term=E6201&rank=2 [Last accessed 04 September 2013]
29. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009;10:1236-42
30. Anacor's Pipeline, Anacor Pharmaceuticals, Inc. 2013. Available from: http://www.anacor. com/an2728.php [Last accessed 04 September 2013]
31. Kogan TP, Dupre B, Bui H, et al. Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)- 4-(2-alpha-Dmannopyranosyloxy) phenyl]hexane (TBC1269). J Med Chem 1998;41:1099-111
32. Friedrich M, Bock D, Philipp S, et al. Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res 2006;297:345-51
33. Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis. Revotar Biopharmaceuticals AG. 2009. Available from: http://clinicaltrials. gov/ct2/show/NCT00823693? term=Bimosiamose&rank=3 [Last accessed 04 September 2013]
34. Stewart DG, Lewis HM. Vitamin D analogues and psoriasis. J Clin Pharm Ther 1996;21:143-8
35. Berth-Jones J, Hutchinson PE. Vitamin D analogues and psoriasis. Br J Dermatol 1992;127:71-8
36. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93
37. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-23
38. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005;53:S17-25
39. Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris. 2013. Available from: http:// clinicaltrials. gov/show/NCT00817219 [Last accessed 03 September 2013]
40. To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis. GlaxoSmithKline plc. 2013. Available from:
41. PK and PD Study of Calcitriol 3 Mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis. Galderma SA. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT01766440? term=calcitriol+ointment +psoriasis&rank=5 [Last accessed 03 September 2013]
42. LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris. LEO Pharma. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01866163? term=LEO +90100&rank=3 [Last accessed 04 September 2013]
43. Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients. Maruho Co. Ltd. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT01844973 [Last accessed 04 September 2013]
44. Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients Marhuo Co. Ltd. 2012. Available from: http://clinicaltrials. gov/ct2/show/NCT01301157 [Last accessed 04 September 2013]
45. Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients. Maruho Co. Ltd. 2010. Available from: http://clinicaltrials.gov/ct2/ show/NCT00884169 [Last accessed 04 September 2013]
46. Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis. Maruho Co. Ltd. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT01873677 [Last accessed 04 September 2013]
47. Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis. Maruho Co. Ltd. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT01878461. [Last accessed 04 September 2013]
48. Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis. Maruho Co. Ltd. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT01908595 [Last accessed 04 September 2013]
49. Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol 2012;26:1516-21
50. Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis. Almirall, S.A. 2010. Available from: http://clinicaltrials. gov/ct2/show/NCT01119339? term=LAS41004&rank=1 [Last accessed 04 September 2013]
51. Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis. Almirall SA. 2011. Available from: http://clinicaltrials. gov/ct2/show/NCT01283698? term=LAS41004&rank=2 [Last accessed 04 September 2013]
52. Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test. Almirall SA. 2011. Available from: http://clinicaltrials.gov/ct2/ show/NCT01360944?term=LAS41004&rank=3 [Last accessed 04 September 2013]
53. Efficacy and Tolerability of LAS41004 Formulations in a Nonocclusive Psoriasis Plaque Test (PPT4) Almirall SA. 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT01462643?term=LAS41004&rank=4 [Last accessed 04 September 2013]
54. Randomized Study of PH-10 for Psoriasis. Provectus Pharmaceuticals, Inc. 2012. Available from: http://clinicaltrials. gov/ct2/show/NCT01247818?term=PH- 10&rank=1 [Last accessed 04 September 2013]
55. PH-10 for psoriasis. Provectus Pharmaceuticals, Inc. 2012. Available from: http://www.pvct. com/ph10psoriasis.html [Last accessed 01 August 2013]
56. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164:1091-6
57. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26(Suppl 3):61-7
58. Kivelevitch DN, Tahhan PV, Bourren P, et al. Self-medication and adherence to treatment in psoriasis. Int J Dermatol 2012;51:416-19
59. Thorneloe RJ, Bundy C, Griffiths CE, et al. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol 2013;168:20-31
60. Martin SL, McGoey ST, Bebo BF Jr, Feldman SR. Patients' educational needs about topical treatments for psoriasis. J Am Acad Dermatol 2013;68:e163-8